Payment overview · 2025
General Payments
$4,401.88
102 reported records · 20 companies
Healthcare provider profile · identity verified
Joseph Lowell Thomas, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TORRANCE, CA · NPI 1568641660
Verified facts
What the public records show
CMS Open Payments records show Joseph Lowell Thomas, MD received $4,401.88 in general payments during 2025 across 102 reported records.
Medtronic, Inc. accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,663.46 | 37.8% | 50 | 2025 |
| AOP Health US, LLC | Unresolved — no canonical attribution shown | $839.36 | 19.1% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $440.12 | 10.0% | 5 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $344.35 | 7.8% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $259.30 | 5.9% | 12 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $246.25 | 5.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $166.79 | 3.8% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $59.27 | 1.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.03 | 1.3% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $51.57 | 1.2% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $43.68 | 1.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.34 | 0.9% | 2 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $31.36 | 0.7% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $30.48 | 0.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.33 | 0.7% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $29.13 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.13 | 0.4% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $18.94 | 0.4% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $15.21 | 0.3% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $14.78 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,401.88 | 102 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $1,630.88 | 47 | 2025 |
Source payment records
|
|||||
| Rapiblyk Normalized: rapiblyk |
Drug | AOP Health US, LLC | $839.36 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $440.12 | 5 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $246.25 | 2 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $101.70 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY Normalized: synergy |
Device | Boston Scientific Corporation | $96.78 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $59.27 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $58.37 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $51.57 | 2 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $46.11 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $33.74 | 2 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $31.36 | 1 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $30.48 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.33 | 1 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $29.13 | 1 | 2025 |
Source payment records
|
|||||
| TR BAND Normalized: tr band |
Device | Terumo Medical Corporation | $29.13 | 1 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $27.44 | 3 | 2025 |
Source payment records
|
|||||
| PULSESELECT Normalized: pulseselect |
Device | Medtronic, Inc. | $26.02 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $19.83 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Wolverine Coronary Cutting Balloon Normalized: wolverine coronary cutting balloon |
Device | Boston Scientific Corporation | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $13.01 | 1 | 2025 |
Source payment records
|
|||||
| MAMBA Normalized: mamba |
Device | Boston Scientific Corporation | $12.83 | 1 | 2025 |
Source payment records
|
|||||
| EPSILA EV Normalized: epsila ev |
Device | Medtronic, Inc. | $6.56 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $2.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,401.88 · 102 records | Medtronic, Inc. | ANGIO-SEAL, AVVIGO Guidance System, Attruby, CARDIVA VASCADE MVP XL VVCS 10-12F, COROFLOW, DRAGONFLY OPSTAR, ELIQUIS, EPSILA EV, EVKEEZA, FUROSCIX, GALLANT, General - Atherectomy, General - Stents, IBSRELA, KENGREAL, Kcentra, LifeVest, MAMBA, MICRA, PEMGARDA, PRESSUREWIRE, PULSESELECT, RESONATE EL ICD VR, ROTAPRO, Rapiblyk, SAPIEN 3 Ultra RESILIA, SYNERGY, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TR BAND, VERQUVO, VYNDAQEL, WAINUA, Wolverine Coronary Cutting Balloon | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error